US/UK/Canada

Share

Pick a time period -
Tags ( Active)

LinkMed acquire major sales channel

LinkMed acquires NorDiag´s 50 percent stake in Olerup International AB, which is the holding company for Olerup GmbH. LinkMed will thereby control 75 percent of the company. Both sales and earnings are consolidated into the Group as of June 1, 2011. Net sales are expected to increase on an annual basis by approximately SEK 28 million and the profit on EBIT level of SEK 8-10 million.LinkMed increases its ownership in Olerup International AB to 75 percent by acquiring NorDiag 50 percent stake in Olerup International AB which is the holding company of Olerup GmbH. The remaining 25 percent of

Olerup SSP broadens its portfolio with HLA Sequencing Based Typing products from Australian company Conexio

LinkMed transplantation company Olerup SSP has signed an exclusive five-year global marketing, sales and distribution agreement with the Australian company Conexio for Conexio’s SBT Resolver™- HLA Sequencing Based Typing product line and sequence analysis software. Olerup SSP will now be able to broaden its product offer towards the HLA community.Conexio’s SBT Resolver™ products are locus specific PCR based HLA sequencing based typing (SBT) reagents. The agreement includes SBT kits and a version of Assign™ sequence analysis software. The SBT product line will be a strong complement to the

Olerup SSP extends its product portfolio through a new exclusive sales agreement

LinkMed’s transplantation company, Olerup SSP, has signed an exclusive sales agreement with the American company Biotium for their product GelRed™. The sales agreements gives Olerup SSP the exclusive rights to sell GelRed™ to the HLA typing market. GelRed™ is an environmentally safe and ultrasensitive fluorescent nucleic acid gel stains designed to replace the highly toxic ethidium bromide (EtBr).Developed by Biotium, GelRed™ is superior to EtBr and other EtBr alternatives by having a combination of low toxicity, high sensitivity and exceptional stability. GelRed™ is a sensitive, stable and

Interim report January - September 2010

· LinkMed decided to change the strategic focus of its operations, putting further focus on the transplantation sector, while intensifying and accelerating efforts to harvest the value of its associated companies. The change in strategy resulted in restructuring costs of SEK 6.3 million, charged to earnings in the third quarter. The restructuring carried out so far will result in an annual decrease in costs of SEK 7 million. · Net sales for the period amounted to SEK 60.6 million (64.1). Currency effects had a negative impact on sales of SEK 7 million. · Net sales for the third

Increased focus on the transplantation sector

The Board of Directors of LinkMed today announced a strategic decision to further focus the company’s operations on the transplantation sector. Consequently, LinkMed will work actively to find additional acquisitions in the sector and continue its global efforts in Olerup SSPs and AbSorber’s product area. Going forward, LinkMed will prioritize investment in this sector. At the same time, the company will intensify work to realize the value of the portfolio of life science companies built up since 1998. In the long-term, LinkMed’s operations will essentially be focused on the transplantation

Interim report January – June 2010

Transplantation sector operations in the second quarter · OLERUP SSP’s sales growth in local currencies rose by 11 percent in the second quarter compared to the corresponding period last year. Sales in Europe rose by 3 percent and sales in North America were up 47 percent. Net sales in Swedish kronor amounted to SEK 19.8 million (20.0) in the second quarter. · AbSorber and the U.S. sales company Olerup Inc. are included in full in the consolidated financial statements for the second quarter. The consolidated results are affected by costs related to the sales organization and

Likvor first international order

LinkMed’s portfolio company Likvor has received its first order for the Likvor CELDA™ system from a customer outside Sweden. The order comes from Aalborg Hospital which is the largest hospital in the North Denmark Region. This is the fifth order for the instrument since it got CE marked in September, 2009. With Likvor CELDA™ the clinic will be able to measure the dynamics of the most important parameters concerning the patients’ cerebrospinal fluid including pressure and flow in a controlled and safe process. Likvor CELDA™ was developed to facilitate greater understanding and enhance

AbSorber receives European patent protection for its transplantation cross match-test XM-ONE

LinkMed’s subsidiary AbSorber has received patent protection for its transplantation cross match-test XM-ONE® in the European countries. The patent was previously approved in New Zealand which was the first country to approve a patent for AbSorbers product. The European countries are highly prioritized markets for AbSorber and the patent approval is an important milestone in Absorbers intellectual property strategy.The patent was granted by the European Patent Office (EPO) and AbSorber has also patent applications pending for XM-ONE® in the US, Japan and in other key transplantation markets.

Olerup SSP’s entire HLA typing range now ready for sales in the U.S.

Olerup SSP, a wholly owned subsidiary of LinkMed, has had its Taq-polymerase-free HLA typing kit registered and cleared by the FDA. This means that Olerup SSP’s entire product range for HLA typing, with or without Taq polymerase, can now be marketed and sold to a greater number of healthcare centers in North America. The U.S. is the single largest market for HLA typing and represents over 40 percent of the global tissue typing market. Olerup SSP’s HLA typing kit with Taq polymerase has been approved by the FDA for sale in the United States since March 2009.“Olerup SSP’s products are

Likvor’s technology supports the diagnosis of hidden disease

LinkMed’s portfolio company Likvor has been granted CE marking for its instrument for better and safer identification and diagnosis of Normal Pressure Hydrocephalus (NPH). The instrument, CELDA, was developed to assess the dynamics – pressure, flow and resistance – of cerebrospinal fluid (CSF) surrounding the brain and spinal cord. CELDA facilities greater understanding and enhanced diagnosis of NPH, a condition that is often mistaken for dementia. CE marking opens up the European market for the product.CELDA(TM) is the first commercially approved instrument for assessing the flow of CSF

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Media